HLA-E and cancer: In this scenario, the distinctive molecular characteristics of RNA polymerase I inhibitors, including their capacity to modulate HLA-E presentation, enhance the expression of NK cell-activating ligands, and influence macrophage polarization, present promising avenues for the development of innovative cancer therapies.